Aktienanalyse zu OraSure Technologies Inc (OSUR)OSUROraSure Technologies Inc

OraSure Technologies, Inc. transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its products and services include OraQuick ADVANCE Rapid HIV 1/2 Antibody Test, OraQuick HIV Self-Test, Diagnostics Direct Syphilis Health Check, OraQuick Ebola Rapid Antigen Test, InteliSwab COVID-19 Rapid Test Pro, and SickleSCAN Test, among others. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

OraSure Technologies Inc is currently a hold. The stock is trading at $3.45, significantly below its 52-week high of $4.58, indicating potential for recovery. However, the RSI is at 22.17, suggesting it is oversold, which could lead to a short-term bounce. The recent return to profitability in Q2 2026, with a net income of $6.2 million, is a positive sign, but ongoing challenges remain, such as the hedge funds selling at an increased rate of 2277.4%.

5 analysts cover OSUR: 4 rate it Buy, 1 Hold and 0 Sell.